

## **ADDENDUM TO PSORIASIS ECONOMIC ANALYSIS FOLLOWING CHANGE IN PRICE FOR INFLIXIMAB**

*The only analysis affected by the price change to infliximab is Section 6.3.5 as this is the only analysis in which infliximab is used as a comparator.*

### **6.3.5 Alternative Scenario IV: comparison of biologics with other systemic therapies (patients with any baseline DLQI and assumption that non-responding patients are hospitalised for 21 days per year)**

The final scenario widens the basis of comparison to include all systemic therapies for which effectiveness parameters could be estimated in the evidence synthesis (see Section 4.5). As well as supportive care and therapies based on etanercept and efalizumab, this scenario includes methotrexate, ciclosporin, Fumaderm and infliximab. By way of illustration, the scenario is run for all patients (regardless of baseline DLQI) and assuming that patients not responding to therapy are hospitalised for 21 days per annum.

Table 6.3.13 shows the expected QALYs, costs and ICERs for this scenario. As a result of their higher effectiveness (compared to supportive care) and lower acquisition costs (compared to the biologics), methotrexate, ciclosporin and Fumaderm all dominate supportive care. The ICERs for etanercept-based therapies and efalizumab, compared to supportive care, are similar to those in Alternative Scenario II. The ICER of infliximab, compared to supportive care, is similar to that of etanercept 25mg (continuous).

Table 6.3.14 show the most cost-effective treatment sequences, conditional on the threshold for cost-effectiveness, for this broader comparison. It shows that methotrexate, ciclosporin and Fumaderm would be the first three treatments in the sequence whatever threshold value is used. The first biologic to appear is etanercept 25mg (4<sup>th</sup> in sequence at £30,000 per QALY gained). Etanercept 25mg (continuous) and efalizumab appear 5<sup>th</sup> and 6<sup>th</sup> in the sequence, respectively, at a threshold of £50,000 and above. Etanercept 50mg does not appear in any sequence at the

thresholds used in the analysis. Table 6.3.15 shows the results of the probabilistic sensitivity analysis for this scenario, and indicates that the probabilities of being first in sequence and of appearing in the sequence are highest for methotrexate, ciclosporin and Fumaderm.

**Table 6.3.13. Results of the base-case analysis including supportive care and full range of systemic therapies. Includes all patients (regardless of baseline DLQI) and assumes that patients not responding to therapy are hospitalised for 21 days per year. All etanercept therapies are intermittent unless stated and efalizumab is continuous.**

	QALYs			Costs			ICER	ICER against Supportive Care
	Mean	2.5% CI	97.5% CI	Mean	2.5% CI	97.5% CI		
<b>Methotrexate</b>	0.126	0.07	0.183	-4218	-4593	-3249	-	Dominates
<b>Ciclosporin</b>	0.123	0.071	0.175	-449	-798	16	Dominated	Dominates
<b>Fumaderm</b>	0.102	0.038	0.161	-191	-2154	2231	Dominated	Dominates
<b>Supportive Care</b>	0	0	0	0	0	0	Dominated	-
<b>Etanercept 25mg</b>	0.117	0.066	0.169	3409	2619	4976	Dominated	29210
<b>Efaluzimab</b>	0.112	0.064	0.161	5237	4651	6095	Dominated	46700
<b>Etanercept 25mg Continuous</b>	0.117	0.066	0.169	5332	4751	6486	Dominated	45693
<b>Infliximab</b>	0.134	0.078	0.192	6169	3760	8915	1292966	45936
<b>Etanercept 50mg</b>	0.124	0.072	0.176	10256	9713	11248	Dominated	82994

**Table 6.3.14. Most cost-effective ordering of therapies for Alternative Scenario IV as a function of threshold value for cost-effectiveness. Analysis includes supportive care and full range of systemic therapies. Includes all patients (regardless of baseline DLQI) and assumption that patients not responding to therapy are hospitalised for 21 days per annum. All etanercept therapies are intermittent unless stated and efalizumab is continuous.**

Threshold value of cost-effectiveness	1 <sup>st</sup> in sequence	2 <sup>nd</sup> in sequence	3 <sup>rd</sup> in sequence	4 <sup>th</sup> in sequence	5 <sup>th</sup> in sequence	6 <sup>th</sup> in sequence	7 <sup>th</sup> in sequence	8 <sup>th</sup> in sequence
0	Methotrexate	Ciclosporin	Fumaderm	Supportive Care				
5000	Methotrexate	Ciclosporin	Fumaderm	Supportive Care				
10000	Methotrexate	Ciclosporin	Fumaderm	Supportive Care				
15000	Methotrexate	Ciclosporin	Fumaderm	Supportive Care				
20000	Methotrexate	Ciclosporin	Fumaderm	Supportive Care				
25000	Methotrexate	Ciclosporin	Fumaderm	Supportive Care				
30000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Supportive Care			
35000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Supportive Care			
40000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Supportive Care			
45000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Supportive Care			
50000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Infliximab	Etanercept 25mg Continuous	Efaluzimab	Supportive Care
55000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Infliximab	Etanercept 25mg Continuous	Efaluzimab	Supportive Care
60000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Infliximab	Etanercept 25mg Continuous	Efaluzimab	Supportive Care
65000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Infliximab	Etanercept 25mg Continuous	Efaluzimab	Supportive Care
70000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Infliximab	Etanercept 25mg Continuous	Efaluzimab	Supportive Care
75000	Methotrexate	Ciclosporin	Fumaderm	Etanercept 25mg	Infliximab	Etanercept 25mg Continuous	Efaluzimab	Supportive Care

**Table 6.3.15. Results of probabilistic sensitivity analysis for Alternative Scenario IV showing probabilities that each therapy is first in sequence and included in the sequence at all conditional on the threshold value of cost-effectiveness. Analysis includes supportive care and full range of systemic therapies. Includes all patients (regardless of baseline DLQI) and assumption that patients not responding to therapy are hospitalised for 21 days per annum. All etanercept therapies are intermittent unless stated and efalizumab is continuous.**

Threshold value of cost-effectiveness		Etanercept 25mg	Etanercept 50mg	Efalizumab	Supportive Care	Ciclosporin	Methotrexate	Fumaderm	Infliximab	Etanercept 25mg Continuous
20000	Probability first in	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
30000	sequence	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00	0.00
50000		0.00	0.00	0.00	0.00	0.01	0.99	0.00	0.00	0.00
20000	Probability included	0.09	0.00	0.00	1.00	1.00	1.00	0.92	0.00	0.00
30000	in sequence	0.56	0.00	0.02	1.00	1.00	1.00	0.96	0.09	0.03
50000		0.93	0.00	0.60	1.00	1.00	1.00	0.97	0.46	0.63

